Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Stuttgart - Delayed Quote • EUR BeiGene Ltd (49BA.SG) Follow Compare 248.00 +22.00 +(9.73%) At close: 8:41:34 AM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations US Stocks Trading Below Estimated Value In February 2025 As of February 2025, the U.S. stock market has experienced a mixed performance with recent declines following record highs for major indices like the S&P 500. This fluctuation presents an opportunity to explore stocks that may be trading below their estimated value, particularly in a market environment where identifying companies with strong fundamentals and potential for growth can be key to making informed investment decisions. High Growth Tech Stocks in the United States to Watch Over the last 7 days, the United States market has risen by 1.2%, contributing to a substantial climb of 24% over the past year, with earnings anticipated to grow by 15% annually. In such a robust market environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability in rapidly evolving sectors. BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27 SAN MATEO, Calif., February 13, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with BeiGene management at 8:00 a.m. ET. Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:ONC) 41% Undervaluation? Key Insights The projected fair value for BeiGene is US$376 based on 2 Stage Free Cash Flow to Equity BeiGene is... Discover 3 US Stocks Including Microchip Technology That May Be Trading Below Estimated Fair Value As the U.S. stock market approaches record highs, driven by a surge in AI-related stocks and strong earnings reports, investors are keenly searching for opportunities that might be trading below their estimated fair value. In this environment, identifying undervalued stocks requires careful analysis of fundamentals and potential growth prospects amid the broader market rally. Exploring High Growth Tech Stocks in January 2025 The United States market has experienced a notable upswing, climbing by 3.8% over the past week and achieving a 24% increase over the last year, with earnings forecasted to grow by 15% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these positive market trends. When Can We Expect A Profit From BeiGene, Ltd. (NASDAQ:ONC)? With the business potentially at an important milestone, we thought we'd take a closer look at BeiGene, Ltd.'s... BeiGene Stock Meets 80-Plus RS Rating Benchmark BeiGene stock just hit that mark, with a jump from 69 to 84 Wednesday. Is BeiGene Stock A Buy? BeiGene stock reclaimed its 50-day moving average on Tuesday and is working on a consolidation with a 248.16 entry. BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe BASEL, Switzerland, January 06, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1st. This appointment will enhance the Company’s commitment to bring impactful medicines to more patients across Europe. TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy SAN MATEO, Calif., December 27, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose Exploring Three High Growth Tech Stocks In The United States Over the last 7 days, the United States market has dropped 2.2%, yet it is up 24% over the past year with earnings forecasted to grow by 15% annually. In such dynamic conditions, identifying high growth tech stocks involves looking for companies with robust innovation and strong potential to capitalize on emerging trends in technology. With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns Key Insights Institutions' substantial holdings in BeiGene implies that they have significant influence over the... BeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference SAN MATEO, Calif., December 23, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to "ONC" on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor SAN MATEO, Calif., December 13, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. ("CSPC") for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets SAN MATEO, Calif., December 10, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring its leadership in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) through continued clinical success with BRUKINSA® (zanubrutinib) and promising advancements in BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL SAN MATEO, Calif., December 04, 2024--BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024 SAN MATEO, Calif., December 02, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will host an investor webcast on December 16, 2024 at 8:30 am EST. The Company’s R&D leadership team will provide an update on BeiGene’s innovative portfolio and pipeline, focusing on key presentations at the American Society of Hematology Meeting (ASH) and the San Antonio Breast Cancer Symposium. European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer SAN MATEO, Calif., November 27, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. BeiGene to Present at Upcoming Investor Conferences SAN MATEO, Calif., November 26, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will participate in fireside chats at two upcoming investor conferences: High Growth Tech Stocks to Watch in November 2024 Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has climbed an impressive 32%, with earnings expected to grow by 15% per annum in the coming years. In this environment of robust growth, identifying high-growth tech stocks that can capitalize on these trends requires a focus on innovation, scalability, and strong financial health. Performance Overview Trailing total returns as of 2/21/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX Return 49BA.SG HANG SENG INDEX YTD +42.53% +17.04% 1-Year +82.35% +42.26% 3-Year +37.02% -2.86%